Report #2838121

Overview

Sex

Unknown

Age

Age unknown

State

IN

Recovered

Unknown

Vaccinated

—

Onset

—

Days to onset

—

Hospital days

—

Symptoms (1)

Symptom narrative

Intramuscular administration of Priorix; This non-serious case was reported by a other health professional via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a specified number of patients who received MMR (Priorix) for prophylaxis. On an unknown date, the patient received Priorix (intramuscular). On an unknown date, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: Intramuscular administration of Priorix). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 21-APR-2025 On 21 Apr 2025, a clinical pharmacy manager called to inform the following about Priorix unfortunately some of them have been administered intramuscularly which led to Subcutaneous injection formulation administered by other route. The reporter clarified that two patients had received Priorix via intramuscular administration. The gender of the patients was unknown, as well as other details such as lot number, expiration date or date of administration.